However, autologous SCT has only limited success when performed in refractory or progressive stage disease or in heavily pretreated or multiple relapsed patients. The expected longterm disease-free survival in these settings is 0-20%. 2 An international consensus conference determined that autologous SCT is inappropriate in chemo-refractory first or subsequent relapse. 3 Allogeneic SCT offers a potentially curative option to patients with lymphoma by providing high-dose chemotherapy as well as a graft-versus-lymphoma (GVLy) effect. 4 Allogeneic SCT may be a therapeutic option for patients with chemo-refractory aggressive lymphoma and for patients failing a prior autologous SCT. It also may be offered as an option to cure patients with indolent lymphoma, where autologous SCT is not considered curative. 5 However, allogeneic SCT with standard myeloablative conditioning has been associated, historically, with high non-relapse mortality (NRM) rates of up to 50%, and even higher in patients failing a prior autologous SCT. 6, 7 Reduced-intensity conditioning (RIC) regimens have been designed to provide sufficient immune suppression to allow engraftment of donor cells and to exploit the GVLy effect as the primary curative approach. 8 RIC regimens have allowed wide use of allogeneic SCT in patients with lymphoma. 5, [9] [10] [11] [12] [13] [14] [15] However, this approach is of limited success in patients with bulky, chemo-resistant disease. 5, 14, 15 In this setting, as well as in patients with active aggressive histologies, the tumor burden must be sufficiently reduced to prevent rapid disease progression after SCT. Effective GVLy effect may require a few months to evolve and the disease may progress during this period. 16 Methods for better eradication of the underlying disease and prevention of recurrence while maintaining the low toxicity of RIC are needed to improve outcome. Better cytoreduction of the underlying malignancy may also improve the outcome of patients with chemosensitive disease and low tumor bulk, provided that NRM is not increased.
The monoclonal antibody rituximab, targeting CD20, has become an integral part of primary therapy for aggressive as well as indolent lymphomas and has also been incorporated into various stages of autologous and allogeneic SCT. Lymphomas are inherently radiosensitive malignancies. Radio-labeled antibodies such as yttrium-90 ibritumomab tiuxetan (Zevalin) and iodine-131 tositumomab (Bexxar) are increasingly used in indolent lymphomas, but are also effective in aggressive lymphomas. 17 The initial studies using radioimmunotherapy in combination with high-dose chemotherapy and autologous SCT show promising results. [18] [19] [20] [21] [22] In this study, we explored the use of standard-dose Zevalin combined with RIC and allogeneic SCT in patients with chemorefractory lymphoma expected to have poor outcome with standard SCT.
Patients and methods

Patient eligibility
This phase I-II study was designed to include 12 patients with CD20
þ -non-Hodgkin's lymphoma given allogeneic SCT. Patients could have any lymphoma histology and had to have failed at least two chemotherapy regimens. Patients with follicular lymphoma or small lymphocytic lymphoma were offered allogeneic SCT after failing previous treatments or following disease transformation. Patients with mantle cell lymphoma were eligible if they did not achieve CR with initial therapy. Patients with diffuse large cell lymphoma were eligible only after the failure of a prior autologous SCT. Patients were included only if they had a disease which was chemo-refractory to either initial chemotherapy or after relapse and were required to have active disease demonstrated on PET-CT at the time of SCT. Patients with active CNS disease were not eligible. Chemo-resistance was defined as having less than a 50% reduction in the bidimensional measurements of the largest mass. Patients with an increase of more than 25% in the bidimensional measurements after the last line of chemotherapy were defined as having progressive disease and all others were defined as having stable disease. Bulky disease was defined as any mass larger than 7 cm. There was no limit on the number and type of prior therapies. Unlike standard criteria for treatment with Zevalin, extensive bone marrow involvement and pancytopenia did not exclude treatment, as patients were given allogeneic stem cells after the completion of the treatment plan. Patients were considered not to be good candidates for myeloablative conditioning based on advanced age (450 years), extensive prior therapy or comorbidities. However, patients were required to be free of marked organ dysfunction and to have an ECOG performance score of 0-1 by standard institutional eligibility criteria for allogeneic SCT. Patients had to have an HLA-matched or 1-antigen-mismatched related or unrelated donor willing to donate G-CSF mobilized PBSC (the preferred requested option) or BM. All patients gave a written informed consent and the study was approved by the institutional review board.
Treatment protocol
Rituximab 250 mg/m 2 followed by Zevalin 0.4 mCi/kg (capped at 32 mCi) were given on day À14. Dosimetry was not used and there were no dose adjustments based on blood counts or other criteria. The study medication was supplied free of charge by Bayer Schering Pharma (Berlin, Germany). Reduced-intensity conditioning was started on day À6 and consisted of fludarabine (30 mg/m 2 on days À6 to À2) combined with i.v. BU (3.2 mg/kg daily on days À4 to À3) or melphalan (50-70 mg/m 2 on days À3 to À2). Patients who had a prior autologous SCT (all conditioned with the BEAM regimen containing high-dose melphalan) as well as patients with follicular lymphoma were conditioned with fludarabine/BU. All others were conditioned with fludarabine/melphalan. Patients with an unrelated or mismatched donor were also given antithymocyte globulin (ATG, Fresenius, 5 mg/kg given on days À3 to À1). Phenytoin was administered from the day before and until 24 h after the completion of BU infusion. Prophylaxis against GVHD consisted of CYA and a short course of MTX (15 mg/m 2 on day þ 1 and 10 mg/m 2 on day þ 3 and þ 6). GVHD prophylaxis was administered for 3 months and tapered afterwards in patients with no active GVHD. G-CSF was administered from day þ 7 until engraftment. A standard regimen of antibiotic prophylaxis was used to prevent bacterial, viral, fungal and pneumocystis infections. Patients with residual positron emission tomography (PET) positive masses after SCT were allowed consolidation treatment with external radiotherapy for 1-2 masses or a course of rituximab and this was not considered as an event in the analysis of progression-free survival.
Evaluation of response
Neutrophil and platelet engraftment were defined as the first of three days with an absolute neutrophil count (ANC) 40.5 Â 10 9 /l and the first of 7 days with an untransfused platelet count 420 Â 10 9 /l, respectively. Toxicity after SCT was graded by the National Cancer Institute's (NCI) common toxicity criteria (NCI, Bethesda, MD, USA). Acute and chronic GVHD were graded and staged by the standard criteria. Chimerism was tested using FISH with X and Y chromosome probes in sex-mismatched transplants and with PCR analysis of microsatellite markers in sex-matched transplants. Patients were assessed for disease involvement by PET-CT and BM biopsy (in patients with a history of marrow involvement) prior to SCT, every 3 months during the first year after SCT and every 6 months during the second year or as clinically indicated. CR was defined as the complete disappearance of all PET positive masses and clearance of marrow disease when applicable. Partial response was defined as more than a 50% decrease in bidimensional measurements but residual PET positivity.
Statistical analysis
The primary end point of this study was the safety profile of this regimen. Response and survival rates are presented although the study was not powered due to its limited size to accurately assess these end-points. Overall survival (OS) was calculated from the day of SCT until death or last follow-up. Progression-free survival (PFS) was calculated from the day of SCT until disease progression, death or last follow-up. The probabilities of OS and PFS were estimated using the Kaplan-Meier method. 23 Non-relapse mortality was defined as any death in remission that was not related to disease activity (for example organ toxicity, GVHD, infection). Relapse mortality was defined as death occurring after relapse even when caused by complications related to treatment of relapse. Relapse and non-relapse mortality rates were estimated using cumulative incidence analysis and were considered competing risks. 24 In the analysis of the cumulative incidence of GVHD, relapse with early taper of immune suppression was considered a competing risk.
Results
Patient and disease characteristics
Twelve patients were enrolled in the study between August 2004 and October 2006. Patient and disease characteristics are outlined in Table 1 . The median age was 54 years (range, 37-62). Histologies were small lymphocytic lymphoma (n ¼ 4) in Richter's (n ¼ 3) or prolymphocytic transformation (n ¼ 1), diffuse large B-cell lymphoma (n ¼ 3), follicular lymphoma (n ¼ 3) and mantle cell lymphoma (n ¼ 2). All patients had chemo-refractory disease to either initial therapy or after relapse with positive PET-CT at the time of SCT. Eight patients even showed disease progression during the last course of chemotherapy. Six patients had bulky disease and three had extensive marrow involvement (comprising more than 25%) at the time of SCT. Patients enrolled were heavily pretreated with a median of four lines of prior chemotherapy (range, 2-6). All patients failed rituximab-containing regimens, only one patient had prior radiation therapy and none had prior radioimmunotherapy. Four patients had also failed a prior autologous SCT (two after less than 3 months from transplantation). Conditioning for prior autologous SCT did not include TBI in any of the patients. The donor was an HLA-matched sibling (n ¼ 6), 1-antigen-mismatched sibling (n ¼ 2) or a matched unrelated donor (n ¼ 4). All patients were given G-CSF mobilized PBSC with a median of 6.5 CD34 þ cells/kg (range, 4.3-12.5).
Engraftment and chimerism
All 12 patients achieved primary engraftment. The median time to ANC 0.5 Â 10 9 /l was 14 days (range, 10-22 days). The median first day of neutropenia was day þ 2 (range, À3 to þ 11), resulting in a median of 13 days of neutropenia (range, 3-17 days). The median first day of neutropenia depended on the conditioning regimen; day þ 2 (range, À2 to þ 5) after fludarabine/melphalan conditioning and day þ 5 (range, À2 to þ 11, P ¼ NS) after fludarabine/BU conditioning, similar to what we reported for the corresponding non-Zevalin-containing regimens. 25 Ten patients achieved platelet engraftment. The median time to platelet 420 Â 10 9 /l was 14 days (range, 11-44 days). At the time of first testing, approximately one month after transplantation, all evaluable patients had complete donor chimerism.
Toxicity and GVHD
There were no infusion reactions associated with Zevalin. One patient died of multiple organ toxicities soon after ASCT. An additional patient had reversible acute renal failure (NCI III) with metabolic encephalopathy. Seven patients had moderate to severe mucositis and required narcotics. There were no other NCI grade III-IV toxicities.
Grade II-IV and III-IV acute GVHD occurred by day þ 100, in eight and five patients, with cumulative incidence of 67% (95 C.I. 45-99%) and 50% (95 C.I. 26-96%), respectively. All five patients with grade III-IV had gastrointestinal GVHD and two of them also had severe hepatic GVHD. The three patients with grade II acute GVHD had single organ involvement of the gastrointestinal tract (n ¼ 2) or the skin (n ¼ 1). Chronic GVHD occurred in four of seven evaluable patients (57%) during the follow-up, two extensive and two limited.
In all, NRM occurred in five patients with a cumulative incidence of 42% (95 C.I. 21-81%) at 2 years after SCT. One patient died of organ toxicity, three patients died of complications related to acute GVHD and one died of chronic GVHD.
Response to therapy
Ten patients are evaluable for response. Six patients achieved CR by the standard criteria defined above which included a negative PET-CT. Four patients achieved PR; two died before response could be evaluated. The overall response rate was 83%. None of the patients achieving CR relapsed. Three of the patients achieving PR progressed and one died of GVHD. Interestingly, two of the patients with disease progression, both with small lymphocytic lymphoma in transformation, responded to immune suppression therapy withdrawal, but both died of complications of GVHD. None of the patients were given donor lymphocyte infusions due to active GVHD after the withdrawal of immune suppression. None of the patients had additional radiation therapy after SCT. In all, the 2-year cumulative incidence of relapse was 25% (95% CI, 9-67%, Figure 1 ). As expected in patients with chemorefractory disease, all events of disease progression occurred within a few months of SCT.
Overall and progression-free survival
With a median follow-up of 21 months (range, 12-37), four patients are alive and eight have died. The actuarial 2-year OS and PFS are both 33% (95% CI, 7-60%) (Figure 2 ). The relatively small number of patients in this study did not allow the analysis of patient or transplant characteristics predicting outcome. However, all three patients with follicular lymphoma are long-term survivors, while patients with other histologies seem to fare less well. Table 2 outlines SCT outcomes by disease histology. Table 3 outlines disease characteristics of the three patients with follicular lymphoma and their outcomes after SCT.
Discussion
This study demonstrates the feasibility of administering Zevalin in standard doses with reduced-intensity conditioning prior to allogeneic SCT in patients with advanced chemo-refractory lymphoma. Patients included in this study were expected to have a dismal outcome. Two-thirds had progressive disease to their last chemotherapy course, an ominous prognostic sign. 5, 14 Half of the patients had bulky disease and one-third had already failed an autologous SCT. With the current approach, engraftment was constant and organ toxicity was acceptable, and not different than that expected with similar non-Zevalincontaining regimens. However, the rates of acute GVHD were high resulting in a substantial rate of non-relapse mortality. Relapse rates were relatively low, which supports the hypothesis that the intensification of conditioning with radioimmunotherapy may improve disease control. In all, 2-year PFS was 33%, a reasonable outcome in such a patient group.
Radiolabeled antibodies are ideal candidates to combine with RIC and allogeneic SCT. Radioimmunotherapy targets radiation to disease sites while limiting exposure of uninvolved critical organs. Thus, radioimmunotherapy may serve to replace TBI or augment RIC regimens without added toxicity to normal tissues optimizing the combination of radiation and chemotherapy. Furthermore, radiolabeled antibodies deliver continuous low-dose radiation, which decays slowly over time. There are data to suggest that lymphoma cells may be more sensitive to this low-dose-rate radiation than to the high-dose-rate radiation associated with external beam radiation. 26 The major toxicity and limiting factor in radioimmunotherapy is myelotoxicity. This is easily reversed by stem cell rescue. Most relapses after SCT occur in previous sites of disease suggesting an important role for targeted therapy to these sites. Radioimmunotherapy can, in certain settings, overcome resistance to non-labeled monoclonal antibodies. Tumor cells, which do not bind the antibody due to poor accessibility such as large or poorly vascularized masses or an aberrant phenotype, can still be eliminated by a crossfire effect from adjacent cells. Finally, heavily pretreated patients may be less cross resistant to radioimmunotherapy than to additional chemotherapy, even in myeloablative doses, given in the conditioning regimen prior to SCT. All these factors make the combination of radioimmunotherapy and RIC highly attractive. Both commercially available antibodies, I-131 tositumomab (Bexxar) and Y-90 ibritumomab tiuxetan (Zevalin) have been explored in autologous SCT protocols in both standard and high doses. The conclusion of most of these studies was that engraftment is not impaired and that disease control might be improved with no added toxicity. However, randomized studies, which are currently in progress, are required to confirm any advantage of radioimmunotherapy given in combination with the conditioning regimen in the autologous setting. In a phase II study of 23 patients with chemo-refractory lymphoma, we used standard-dose Zevalin with high-dose BEAM chemotherapy prior to autologous SCT. 21 The estimated 2-year progression-free survival was 52%, a promising outcome for patients in this setting. Although we could not rule out an increase in NRM, relapse rates were markedly less than expected, translating into improved PFS. Although these results seem better than those achieved in the current study with allogeneic SCT, the patients in this study were not eligible for autologous SCT because they had either failed this approach, had extensive marrow involvement precluding stem cell collection, or had a disease more sensitive to allogeneic SCT such as follicular 10 or mantle cell lymphoma. 12 There is less data regarding the combination of radioimmunotherapy in allogeneic SCT.
131 I linked to anti-CD45 and anti-CD33 and 188 Re linked to anti-CD66 have been used in combination with myeloablative chemotherapy and allogeneic SCT in patients with acute leukemia. [27] [28] [29] Radioimmunotherapy seemed to enable further intensification of the conditioning regimen by targeting radiation to the BM with no additional toxicity. A similar approach has also been tested in RIC. Alpha emitters such as 213 Bi conjugated with anti CD45 or anti-TCR-a/b could replace low-dose TBI in a canine model of nonmyeloablative conditioning. 30 There are only a few preliminary reports of radioimmunotherapy used with RIC in patients with lymphoma. Gopal et al., 31 used standard-dose Zevalin with the Seattle non-myeloablative regimen of fludarabine and low-dose TBI in 14 patients with chemo-refractory lymphoma. During a short follow-up of 6 months, seven patients are progression-free. NRM and GVHD were not increased. Khouri et al., 32 used Zevalin with a fludarabine/CY regimen in seven patients, most with chemosensitive disease. During a median follow-up of 16 months, five patients were progression-free. Fietz et al. 33 reported 2 allogeneic SCTs with Zevalin-RIC, but with only short follow-up demonstrating feasibility of engraftment.
The results of the different studies are difficult to compare, due to heterogeneous groups of patients and disease histology, particularly in relation to chemo-sensitivity. In the largest series of RIC-SCT from the EBMT including 188 patients with various lymphomas, Robinson et al. 5 demonstrated that chemosensitivity was the most important prognostic factor. Patients with chemo-refractory disease had a 2-year PFS of only 19 and 71% of patients progressed in the first year, compared to 55 and 23% of patients with chemosensitive disease, respectively. Best results were achieved in patients with low-grade lymphoma, while patients with high-grade and mantle cell lymphoma fared to a much lesser degree. These results are similar to what we demonstrated on a much smaller scale study. The median time to progression in patients with refractory disease was 144 days. In this study the cumulative incidence of progression was only 25%. This seems low for patients with highly resistant lymphoma and supports an advantage to the radioimmunotherapy-RIC approach. However, the results should be interpreted with caution as the study was not powered, due to its limited size, to assess survival and the early NRM events may have limited the observed relapse rate. All three patients with follicular lymphoma achieved CR and are alive in CR 12-37 months after Zevalin and RIC allogeneic SCT (Table 3 ). The role of allogeneic SCT in follicular lymphoma is still controversial. Although apparently GVly is very effective in follicular lymphoma and can be curative, other approaches may result in prolonged remissions with lower NRM. Radioimmunotherapy is effective even in heavily pretreated patients. In a summary of four Zevalin registration trials, 37% of patients achieved long-term responses (412 months). 34 Achievement of CR, non-bulky disease, and stage I/II disease were significant predicting factors for long-term response. Thus, radioimmunotherapy alone may explain our results in this subgroup. Larger studies with longer follow-up will be required to confirm the promising results of Zevalin RIC in the refractory follicular lymphoma.
The most striking observation in the current study was a high incidence of severe acute GVHD. We can not conclude whether this was related to the use of Zevalin or to a false association in a small patient group. This was an unexpected finding as we expected to observe an incidence which would be similar to what is observed with similar non-Zevalin containing regimens in the range of 20-30%. 25 Furthermore, administration of rituximab before and after SCT may potentially limit the occurrence of GVHD, 35, 36 and one may have expected similar results with Zevalin. Other studies of the radioimmunotherapy-SCT combinations and the limited experience with Zevalin-RIC combination by other groups did not show excess GVHD rates.
Certain factors might have contributed to the increased incidence of GVHD. First, this was a group of heavily pretreated patients with chemo-refractory disease, factors associated with higher incidence of GVHD. Patients with lymphoma have often had higher incidence of NRM after RIC-SCT than patients with leukemia, 5,9,25 probably because of SCT being given in more advanced stages. Also, half of the patients had transplants from unrelated or mismatched donors, which may favor GVHD. When RIC was designed, it was hoped that GVHD rates would be lower than with standard myeloablative conditioning. Acute GVHD is related in part to cytokine release from damaged gastrointestinal tissues which amplifies the allogeneic response. 37 Limitation of mucosal injury with RIC may therefore reduce the incidence of acute GVHD. 38 Mixed chimerism that is often observed in the first few months after SCT may also result in bilateral transplantation tolerance and reduced rate of GVHD. However, it is now acknowledged that GVHD is probably only delayed with RIC and continues to be a major limitation to SCT. 39 Although we did not observe an increase in the expected mucosal injury, the Zevalin-RIC combination may have been more intense and complete chimerism was achieved rapidly, factors that might have promoted GVHD. Perhaps the most reasonable explanation is our policy for early withdrawal of immune suppression after SCT attempting at achieving the GVLy effect rapidly in this very high-risk patient group. Interestingly, the three patients with follicular lymphoma achieved remission without GVHD. Prior treatment with fludarabine might have contributed to limited GVHD as suggested by prior studies. 40 Larger scale studies are needed to confirm this observation. However, if this is confirmed, better methods for prevention of GVHD such as longer use of immune suppression, or the addition of alemtuzumab to the conditioning regimen will clearly be essential for the success of this approach.
In conclusion, radioimmunotherapy combined with RIC and allogeneic SCT is feasible and may be associated with improved disease control in patients with chemo-refractory lymphoma. Better results may be achieved in patients earlier in the course of the disease, patients with indolent histology, and with more effective methods for prevention of GVHD. This approach merits further study in larger scale studies.
